Comparison of Tocilizumab and Anakinra in the Treatment of COVID-19: A Single-Center Experience

Basit Öğe Kaydı
dc.authoridAcat, Bengisu Pinar/0000-0002-2889-3176
dc.authoridCavdar, Ozben/0000-0003-3439-2359
dc.contributor.authorAcat, Murat
dc.contributor.authorCavdar, Ozben
dc.contributor.authorTezce, Ahmet
dc.contributor.authorAcat, Bengisu Pinar
dc.date.accessioned2024-09-29T16:06:39Z
dc.date.available2024-09-29T16:06:39Z
dc.date.issued2022
dc.departmentKarabük Üniversitesien_US
dc.description.abstractAim: The aim of this study was to examine whether a difference between endotracheal intubation, non-invasive mechanical ventilation, high flow oxygen therapy requirements and 28-day mortality rate in severe and critical coronavirus disease 2019 (COVID-19) patients receiving anakinra and tocilizumab treatment. Material and Methods: A total of 70 patients infected with COVID-19, who were treated with tocilizumab and anakinra from April 2020 to March 2021 at Karabuk Training and Research Hospital, were recruited in this retrospective study. Data on patient demographics, comorbidities, treatments, clinical outcomes of the patients' and hemogram findings were retrieved from hospital records. Results: The mean age of the patients was 61.34 +/- 11.8 years. Of the 70 patients, 12 (17.1%) were female and 58 (82.9%) were male. Severe and critical COVID-19 cases were evident in 48 (68.6%), and 22 (31.4%) patients, respectively. The mortality rate in 28 days was not statistically significantly different between the tocilizumab and anakinra groups (p=0.999). Both the necessity of high flow oxygen therapy and non-invasive mechanical ventilation were lower in the tocilizumab group than in the anakinra group (p<0.001, and p=0.002, respectively), while there was no statistically significant difference in the necessity of intubation between the two groups (p=0.999). The length of stay was also significantly shorter in the tocilizumab group (p=0.027). Conclusion: High flow oxygen therapy, non-invasive mechanical ventilation requirements, and length of stay were significantly lower than anakinra in the tocilizumab group. Excessive inflammatory response with cytokine storm features causes severe disease course and worsens prognosis in COVID-19.en_US
dc.identifier.doi10.18678/dtfd.1084026
dc.identifier.endpage120en_US
dc.identifier.issn1307-671X
dc.identifier.issue2en_US
dc.identifier.startpage116en_US
dc.identifier.trdizinid1115664en_US
dc.identifier.urihttps://doi.org/10.18678/dtfd.1084026
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1115664
dc.identifier.urihttps://hdl.handle.net/20.500.14619/6961
dc.identifier.volume24en_US
dc.identifier.wosWOS:001207163500004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherDuzce Univ, Fac Medicineen_US
dc.relation.ispartofDuzce Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnakinraen_US
dc.subjectCOVID-19en_US
dc.subjecttocilizumaben_US
dc.titleComparison of Tocilizumab and Anakinra in the Treatment of COVID-19: A Single-Center Experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu